Recently, pharmacological inhibition of TRPM2 channels was shown to obviously attenuate cognitive deficits in rodent models of diabetes (Thapak et al., 2020), global ischemia (Dietz et al., 2020), chronic cerebral hypoperfusion (Miyanohara et al., 2018), aging (Kakae et al., 2019), epilepsy (Zheng et al., 2020) and AD (Jiang et al., 2018). The gene discussed is TRPM2; the disease is epilepsy.